Global Pulmonary Arterial Hypertension Drugs Market Driven by the Introduction of New Disease Modifying Therapies: Technavio

Technavio has published a new report on the global PAH drugs market from 2017-2021. (Graphic: Business Wire)

???pagination.previous??? ???pagination.next???

LONDON--()--According to the latest market study released by Technavio, the global pulmonary hypertension (PAH) drugs market is projected to grow to USD 4,782.81 million by 2021, at a CAGR of more than 3% over the forecast period.

This research report titled ‘Global Pulmonary Hypertension (PAH) Drugs Market 2017-2021’ provides an in-depth analysis of the market in terms of revenue and emerging market trends. This market research report also includes up to date analysis and forecasts for various market segments and all geographical regions.

 
Pulmonary arterial hypertension (PAH) is a condition with a pulmonary vascular resistance that leads to elevated pulmonary arterial pressures, right ventricular failure, and even death in some cases. The introduction of new disease-modifying therapies and agents with high efficacy is expected to boost the growth of the PAH drugs market.

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.

Based on the mechanism of action, the report categorizes the global pulmonary hypertension drugs market into the following segments:

  • Endothelin receptor antagonists (ERAs)
  • Prostacyclin analogs
  • Phosphodiesterase (PDE) inhibitors
  • Soluble guanylate cyclase (sGC) stimulators

The top three revenue-generating mechanism of action segments in the global pulmonary hypertension drugs market are discussed below:

Endothelin receptor antagonists (ERAs)

Endothelin receptor antagonists occupied a majority 42% of the global pulmonary arterial hypertension drugs market and is expected to increase its share through the forecast period. The dominance can be attributed to the large number of drugs available in this segment,” says Sapna Jha, a lead analyst at Technavio for cardiovascular and metabolic disorders research.

Endothelin is a peptide naturally prepared in the layer of cells that line the heart and blood vessels. In excess, this peptide acts as a powerful vessel constrictor, and targeted ERA therapy is used to keep the endothelin production in PAH patients at an optimum level to maintain the balance.

Prostacyclin analogs

Prostacyclin analogs are the second most widely preferred mechanism of action, projected to be worth USD 1439.04 million by 2021. Prostacyclin analogs are lipid molecules synthesized by prostacyclin synthase and are involved in platelet activation and vasodilation. These drugs act by direct vasodilation of the pulmonary and systematic arterial vascular beds and also exhibits platelet aggregation and smooth muscle cell proliferation. The rising demand for PAH drugs and inclusion of these drugs in the global bodies’ medical list are expected to drive the growth of the market segment.

Phosphodiesterase (PDE) inhibitors

There are a limited number of phosphodiesterase inhibitors for the treatment of pulmonary arterial hypertension. Sildenafil and tadalafil are the two approved drugs, which mainly works by releasing nitric oxide to suppress high blood pressure,” says Sapna.

Vendors in the market are also investing in the development of new drugs in this segment, which should drive the market growth. For instance, Novartis is developing QCC374, which is in its Phase II development stage, and more such launches through the next few years will help the market to grow.

The top vendors highlighted by Technavio’s research analysts in this report are:

  • Actelion Pharmaceuticals
  • DAIICHI SANKYO
  • GlaxoSmithKline
  • Novartis
  • United Therapeutics

Browse Related Reports:

Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as they’re published in addition to all 6,000+ existing reports covering segments like cardiovascular devices, central nervous system, and in-vitro diagnostics. This subscription nets you thousands in savings, while staying connected to Technavio’s constant transforming research library, helping you make informed business decisions more efficiently.

About Technavio

Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.

Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, resellers, and end-users.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com

Release Summary

According to the latest market study released by Technavio, the global pulmonary hypertension (PAH) drugs market is projected to grow to USD 4,782.81 million by 2021, at a CAGR of more than 3%.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com